SG11201405574UA - 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors - Google Patents
4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitorsInfo
- Publication number
- SG11201405574UA SG11201405574UA SG11201405574UA SG11201405574UA SG11201405574UA SG 11201405574U A SG11201405574U A SG 11201405574UA SG 11201405574U A SG11201405574U A SG 11201405574UA SG 11201405574U A SG11201405574U A SG 11201405574UA SG 11201405574U A SG11201405574U A SG 11201405574UA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxy
- hydroxylase inhibitors
- hif hydroxylase
- isoquinoline compounds
- isoquinoline
- Prior art date
Links
- 102000008109 Mixed Function Oxygenases Human genes 0.000 title 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- DXTUTXYCHFWRQC-UHFFFAOYSA-N isoquinolin-4-ol Chemical class C1=CC=C2C(O)=CN=CC2=C1 DXTUTXYCHFWRQC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609022P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029912 WO2013134660A1 (en) | 2012-03-09 | 2013-03-08 | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405574UA true SG11201405574UA (en) | 2014-10-30 |
Family
ID=48014301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405574UA SG11201405574UA (en) | 2012-03-09 | 2013-03-08 | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9409892B2 (en) |
| EP (1) | EP2834220B1 (en) |
| JP (2) | JP6129217B2 (en) |
| CN (1) | CN104470899B (en) |
| AU (1) | AU2013229922B2 (en) |
| CA (1) | CA2866556C (en) |
| IL (1) | IL234544A (en) |
| NZ (1) | NZ700760A (en) |
| SG (1) | SG11201405574UA (en) |
| WO (1) | WO2013134660A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102718708A (en) | 2003-06-06 | 2012-10-10 | 菲布罗根有限公司 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof |
| US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| RS57795B1 (en) | 2012-07-16 | 2018-12-31 | Fibrogen Inc | Crystalline forms of a prolyl hydroxylase inhibitor |
| PT2872487T (en) | 2012-07-16 | 2017-05-15 | Fibrogen Inc | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| HUE049623T2 (en) | 2013-06-06 | 2020-09-28 | Fibrogen Inc | Pharmaceutical formulations of a hif hydroxylase inhibitor |
| WO2015054579A1 (en) * | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Treatment of acute kidney injury with phd1 modulators |
| ES2898476T3 (en) | 2014-09-02 | 2022-03-07 | Sunshine Lake Pharma Co Ltd | Quinolone compound and use thereof |
| CN106146395B (en) | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3- hydroxypyridine compound, preparation method and its pharmaceutical applications |
| CN106146490B (en) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 5- hydroxyl -1,7- naphthyridine compounds, preparation method and its pharmaceutical applications replaced by aryloxy group or heteroaryloxy |
| CN105367435A (en) * | 2015-12-03 | 2016-03-02 | 张伟 | Preparation method for beta-alanine t-butyl ester hydrochloride |
| CN107188875B (en) * | 2016-03-15 | 2020-11-10 | 联化科技股份有限公司 | Preparation method and intermediate of substituted phthalide compound |
| CN106478503A (en) * | 2016-09-29 | 2017-03-08 | 上海勋和医药科技有限公司 | The preparation method of Roxadustat intermediate |
| MA46461A (en) | 2016-10-10 | 2021-04-07 | Bristol Myers Squibb Co | TRICYCLIC SULPHONES AS MMR GAMMA MODULATORS |
| CN107954931B (en) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | Preparation method of nodispat |
| WO2018140186A1 (en) | 2017-01-28 | 2018-08-02 | Kingchem Life Science Llc | A process for preparing 5-phenoxy-1(3h)isobenzofuranone |
| TW201920108A (en) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives |
| CN108084090B (en) * | 2017-12-20 | 2020-03-17 | 北京六合宁远科技有限公司 | Synthetic method of brominated compound containing nitrogen heterocycle as drug intermediate |
| CN112679430B (en) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | Method for preparing isoquinolinones compound |
| CN112679431B (en) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | Method for preparing isoquinolinones compound |
| WO2021073623A1 (en) * | 2019-10-18 | 2021-04-22 | 上海迪赛诺化学制药有限公司 | Method for preparing isoquinolinone compounds |
| CN113754569B (en) * | 2020-06-04 | 2024-07-02 | 四川国为制药有限公司 | Intermediate compound and preparation method and application thereof |
| AR127500A1 (en) | 2021-10-28 | 2024-01-31 | Insilico Medicine Ip Ltd | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF |
| WO2023111990A1 (en) * | 2021-12-17 | 2023-06-22 | Akebia Therapeutics, Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
| WO2023111985A1 (en) * | 2021-12-17 | 2023-06-22 | Akebia Therapeutics, Inc. | Picolinamide compounds as selective phd1 inhibitors, compositions, and methods of use |
| AU2023207157A1 (en) * | 2022-01-13 | 2024-07-25 | Fibrogen, Inc. | Treatment for congestive heart failure |
| WO2024138317A1 (en) * | 2022-12-26 | 2024-07-04 | 中国科学院广州生物医药与健康研究院 | THYROID HORMONE RECEPTOR β AGONIST COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF |
| WO2024222890A1 (en) * | 2023-04-28 | 2024-10-31 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof |
| WO2024222893A1 (en) * | 2023-04-28 | 2024-10-31 | Insilico Medicine Ip Limited | Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof |
| WO2024222881A1 (en) * | 2023-04-28 | 2024-10-31 | Insilico Medicine Ip Limited | Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof |
| CN117486797A (en) * | 2023-11-23 | 2024-02-02 | 传健生物医药(厦门)有限公司 | A key intermediate of roxadustat and a preparation method of roxadustat |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| DE2818423A1 (en) | 1978-04-27 | 1979-11-08 | Hoechst Ag | NEW ISOCHINOLINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
| DE3233424A1 (en) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| ATE149486T1 (en) | 1993-11-02 | 1997-03-15 | Hoechst Ag | SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
| DK0650960T3 (en) | 1993-11-02 | 1997-09-01 | Hoechst Ag | Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as drugs. |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| DE19746287A1 (en) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
| FR2779963A1 (en) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis |
| IT1302677B1 (en) | 1998-10-15 | 2000-09-29 | Zambon Spa | BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
| WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (en) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | DERIVATIVES OF THYROSIN WITH ANTI LEUKOTRIENIC ACTIVITY, PROCEDURES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE. |
| FI20002044A0 (en) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Naphthalene derivatives which inhibit Comt enzymes |
| DE10110750A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
| AU2002312371A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Aryl-benzimidazole compounds having antiinfective activity |
| EP1401817A4 (en) | 2001-06-13 | 2005-11-02 | Genesoft Pharmaceuticals Inc | Isoquinoline compounds having antiinfective activity |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| CA2467689C (en) | 2001-12-06 | 2013-10-01 | Fibrogen, Inc. | Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| CN102718708A (en) * | 2003-06-06 | 2012-10-10 | 菲布罗根有限公司 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof |
| AU2004259675A1 (en) | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine CGRP receptor antagonists |
| US20070042937A1 (en) | 2003-08-01 | 2007-02-22 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| JP2007501844A (en) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | Aryl and heteroaryl compounds, compositions and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| ES2332798T3 (en) | 2004-05-28 | 2010-02-12 | Fibrogen, Inc. | ACTIVITY TEST OF HIFROXYLASE PROLIL HIF. |
| CN101166745A (en) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | Novel thienopyridine compounds, and methods of use thereof |
| CN101849943A (en) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | Use the improved treatment for anemia of HIF alpha stabilizers |
| ATE470439T1 (en) | 2005-06-15 | 2010-06-15 | Fibrogen Inc | USE OF HIF 1ALFA MODULATORS TO TREAT CANCER |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| CN103382216B (en) | 2006-01-27 | 2016-04-20 | 菲布罗根有限公司 | Make the Cyanoisoquinoline compound that hypoxia inducible factor (HIF) is stable |
| CA2647596C (en) | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| EP4095127A1 (en) * | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| MX2011005898A (en) | 2008-12-03 | 2011-09-27 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a. |
-
2013
- 2013-03-08 CN CN201380023358.XA patent/CN104470899B/en active Active
- 2013-03-08 AU AU2013229922A patent/AU2013229922B2/en active Active
- 2013-03-08 US US14/383,874 patent/US9409892B2/en active Active
- 2013-03-08 JP JP2014561149A patent/JP6129217B2/en active Active
- 2013-03-08 SG SG11201405574UA patent/SG11201405574UA/en unknown
- 2013-03-08 CA CA2866556A patent/CA2866556C/en active Active
- 2013-03-08 EP EP13712970.6A patent/EP2834220B1/en active Active
- 2013-03-08 WO PCT/US2013/029912 patent/WO2013134660A1/en active Application Filing
- 2013-03-08 NZ NZ700760A patent/NZ700760A/en unknown
-
2014
- 2014-09-09 IL IL234544A patent/IL234544A/en active IP Right Grant
-
2017
- 2017-03-13 JP JP2017047346A patent/JP2017101089A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104470899B (en) | 2017-12-26 |
| JP2017101089A (en) | 2017-06-08 |
| HK1206743A1 (en) | 2016-01-15 |
| AU2013229922B2 (en) | 2017-09-28 |
| CA2866556A1 (en) | 2013-09-12 |
| US9409892B2 (en) | 2016-08-09 |
| CA2866556C (en) | 2020-01-07 |
| US20150038528A1 (en) | 2015-02-05 |
| EP2834220A1 (en) | 2015-02-11 |
| EP2834220B1 (en) | 2016-11-09 |
| JP6129217B2 (en) | 2017-05-17 |
| WO2013134660A1 (en) | 2013-09-12 |
| NZ700760A (en) | 2016-08-26 |
| AU2013229922A1 (en) | 2014-10-23 |
| CN104470899A (en) | 2015-03-25 |
| JP2015509543A (en) | 2015-03-30 |
| IL234544A (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100035I1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| SG11201405574UA (en) | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors | |
| EP2804479A4 (en) | Metalloenzyme inhibitor compounds | |
| IL239457A0 (en) | Novel heterocyclic compounds as bromodomain inhibitors | |
| LT2892889T (en) | Inhibitor compounds | |
| PL2920149T3 (en) | 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof | |
| EP2948450A4 (en) | Metalloenzyme inhibitor compounds | |
| EP2894981A4 (en) | Metalloenzyme inhibitor compounds | |
| PL2804858T3 (en) | Metalloenzyme inhibitor compounds | |
| SI2912041T1 (en) | Tetrahydropyrrolothiazine derivatives as bace inhibitors | |
| IL239153A0 (en) | Substituted pyridopyrazines as syk inhibitors | |
| EP2847186A4 (en) | Substituted aminoquinazolines useful as kinases inhibitors | |
| ZA201405227B (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| IL237626A0 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| PL2888228T3 (en) | Inhibitors of cd40-traf6 interaction | |
| GB201211019D0 (en) | Inhibitor compounds | |
| IL238739A0 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| EP2879681A4 (en) | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 | |
| TWI561515B (en) | Metalloenzyme inhibitor compounds | |
| IL236946A0 (en) | Inhibitor compounds of phosphodiesterase type 10a |